Cargando…

PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis

BACKGROUND: Programmed cell death ligand-1 (PD-L1) is a predictive marker of anti-PD-1/PD-L1 therapy response. Intra-tumour heterogeneity of PD-L1 expression has been reported in non-small cell lung cancer (NSCLC), but comprehensive studies regarding the determination of PD-L1 expression in differen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Xuxia, Wang, Yue, Jin, Yan, Zheng, Qiang, Shen, Lei, Chen, Ying, Li, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339751/ https://www.ncbi.nlm.nih.gov/pubmed/34422362 http://dx.doi.org/10.21037/jtd-21-388

Ejemplares similares

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
por: Haragan, Alexander, et al.
Publicado: (2019)

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
por: Munari, Enrico, et al.
Publicado: (2017)

Reliability of PD-L1 assays using small tissue samples compared with surgical specimens
por: Kim, Insu, et al.
Publicado: (2019)

Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
por: Munari, Enrico, et al.
Publicado: (2018)

Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
por: Zhao, Yue, et al.
Publicado: (2016)

Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples
por: Kulaç, İbrahim, et al.
Publicado: (2020)

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
por: BULUTAY, Pınar, et al.
Publicado: (2021)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
por: Pagni, Fabio, et al.
Publicado: (2020)

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
por: Xie, Mingying, et al.
Publicado: (2022)

The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
por: ANCIN, Burcu, et al.
Publicado: (2022)

A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer
por: Tsunoda, Akihito, et al.
Publicado: (2019)

ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature
por: Zheng, Qiang, et al.
Publicado: (2018)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
por: Chen, Fang-Fang, et al.
Publicado: (2020)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response
por: Wang, Ying-Nai, et al.
Publicado: (2022)

Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients
por: Xue, Qianqian, et al.
Publicado: (2022)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
por: Ekin, Zübeyde, et al.
Publicado: (2021)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
por: Cai, Yiran, et al.
Publicado: (2020)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR ‐mutated lung adenocarcinoma
por: Kunimasa, Kei, et al.
Publicado: (2023)

MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN
por: Gong, Jiaomei, et al.
Publicado: (2022)

Homogeneous and heterogeneous risk and prognostic factors for lung metastasis in colorectal cancer patients
por: Wang, Hongmei, et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer
por: Rehman, Jamaal A., et al.
Publicado: (2016)

PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
por: Narits, Jaanika, et al.
Publicado: (2020)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2016)

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
por: Vanguri, Rami S., et al.
Publicado: (2022)

PD-L1 and c-MET expression and survival in patients with small cell lung cancer
por: Miao, Lulu, et al.
Publicado: (2017)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients
por: Liu, Chia-Hsin, et al.
Publicado: (2015)

Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases
por: Yu, Yaner, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tdnr90f28hqjsj3bkksatleon1